In the U.S. pushing drugs for unapproved uses has gotten companies into big trouble. In Italy, the opposite is now true. To save money, the government will pay for patients to be treated for an eye disease with Roche's Avastin, a drug not approved for that use, and has taken legal action against the Swiss drugmaker and marketing partner Novartis for steering physicians toward the pricier Lucentis, which is.
A federal court in Canada has now agreed with the industry that the country's price setting board has assumed too much authority and severely curtailed its ability to control prices over generic drugs in a case centered on Novartis' generic drug company Sandoz, and a unit of Teva Pharmaceutical Industries, which started as Ratiopharm.
A health advocacy group has slammed Novartis for falsely advertising its swine antibiotic Denagard, claiming the drug company unnecessarily highlights weight gain in animals--a purpose not approved by the FDA.
Italian finance police searched the offices of the Italian Medicines Agency, looking for evidence in a criminal probe of potential fraud and market manipulation by the Swiss drugmakers Novartis and Roche. Officials have been investigating allegations that the two companies colluded to boost sales of Lucentis, their eye drug, by sidelining off-label use of the drug's close cousin, Avastin.
For an idea of what kind of year a drug developer had, take a look at what it paid its head of R&D. Click through our roundup for a look at who ranks where in the biopharma R&D world. Read more >>
The market for multiple sclerosis drugs is not an easy one, especially now that Biogen Idec's soaring Tecfidera has arrived on the scene. But MS drugmakers Novartis and Merck KGaA are doing what they can to keep their edges, rolling out a pair of digital solutions to help patients manage the disease.
A clutch of Big Pharma companies is backing a competition to create predictive models that could lead to new targets for cancer drugs. Eli Lilly, Novartis and Pfizer are among the data funders of the competition, which calls for the development of models that show how essential a gene is to the survival of a cancer cell.
Novartis wooed one of Merck & Co.'s top executives to take the helm at its oncology unit.
Novartis has to face a kickbacks lawsuit filed by the U.S. Department of Justice, which alleges that the Swiss drugmaker gave pharmacies discounts and rebates to boost sales of two drugs, a federal judge ruled Thursday.
Having made the big decisions about how their database of clinical trial investigators will work, collaborators Eli Lilly, Merck and Johnson & Johnson are looking to add more members to a roster already swelled by the arrival of Novartis and Pfizer.